Prosecution Insights
Last updated: October 04, 2026
Application No. 18/284,252

COLORIMETRIC BIOSENSOR, PREPARATION METHOD THEREOF, AND ANTIBIOTIC SUSCEPTIBILITY TESTING METHOD USING THE SAME

Final Rejection §103
Filed
Sep 26, 2023
Priority
Jan 07, 2022 — RE 10-2022-0002636 +2 more
Examiner
BREEN, KIMBERLY CATHERINE
Art Unit
1657
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Inha University Research And Business Foundation
OA Round
2 (Final)
24%
Grant Probability
At Risk
3-4
OA Rounds
5m
Est. Remaining
81%
With Interview

Examiner Intelligence

Grants only 24% of cases
24%
Career Allowance Rate
19 granted / 80 resolved
-36.2% vs TC avg
Strong +57% interview lift
Without
With
+56.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 5m
Avg Prosecution
39 currently pending
Career history
137
Total Applications
across all art units

Statute-Specific Performance

§101
9.3%
-30.7% vs TC avg
§103
36.2%
-3.8% vs TC avg
§102
8.9%
-31.1% vs TC avg
§112
31.0%
-9.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 80 resolved cases

Office Action

§103
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION The instant claims are entitled to an effective filing date of 12/21/2022. Claims 2-3, and 6 are canceled. Claims 1, 4-5, and 7-15 are pending. Claims 8-9, and 11-15 are withdrawn. Claims 1, 4-5, 7, and 10 are under consideration in this action. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 1, 4-5 and 7 are rejected under 35 U.S.C. 103 as being unpatentable over Jelinek (US 2006/0172371) in view of Lu (US 2019/0240356). Regarding claim 1, Jelinek teaches a calorimetric and/or fluorescent detector comprising one or more polydiacetylenes. See claim 1 of Jelinek. The calorimetric and/or fluorescent detector is in the form of a gel-like solid. See claim 2. Jelinek teaches a porous, gel-like solid organic matrix, which may be used for the detection of a microorganism. See [0012]. The calorimetric and/or fluorescent comprises nutrients required for the growth of microorganism. See claim 7 of Jelinek. The gel-like solid selected from a group that includes agarose (i.e. hydrogel polymer), or other natural or synthetic gelatinous polymers. See claim 6 of Jelinek. For the growth of a microorganism, Jelinek teaches preparing a blue Luria-Bertani (LB)-agar (i.e. a microbial nutrient source that is LB agar). See [0113]. Furthermore, Jelinek suggests that a blue agar matrix can comprise polydiacetylene. See [0098]. Jelinek teaches that the growth (i.e. proliferation) of Salmonella typhimurium wild type, kanamycin-resistant Salmonella typhimurium and E. coli MC4100 strain in an agar matrix containing polydiacetylene and liquids induces a visible color change from blue to red, or the characteristic fluorescence emission. See [0061]. Jelinek does not teach a microbial nutrient source that is encapsulated inside the porous hydrogel structure. Lu teaches a hydrogel-alginate capsule comprising a hydrogel shell and alginate core. See claim 86 of Lu. The hydrogel shell is comprised of polyacrylamide (i.e. a hydrogel polymer) and alginate. See claim 88 of Lu. The hydrogel shell comprises pores. See claim 90 of Lu. The alginate core is infused with nutrients to support cell growth. This can be achieved, for example, by combining the alginate with cell culture media. See [0060]. Lu suggests that the alginate core supports growth by supplying nutrients to bacteria and the hydrogel shell provides mechanical protection for the entire bead. See [0130]. It would have been obvious to a person of ordinary skill in the art prior to the effective filing date of the instantly claimed invention to combine the polydiacetylene and microbial nutrient source of Jelinek with the porous hydrogel shell of Lu for encapulation. One of ordinary skill in the art would have been motivated to do so because Jelinek suggests that the calorimetric and/or fluorescent detector should be capable of supporting the growth of microorganisms (see [0016] of Jelinek), and Lu teaches a hydrogel-alginate capsule in which the alginate core supports bacterial growth (see [0130] of Lu). There would have been a reasonable expectation of success because Jelinek teaches incorporating polydiacetylene into solid frameworks of polysaccharides and polyacrylamides, and Lu demonstrates a hydrogel shell structure comprising an alginate polysaccharide and polyacrylamide. Regarding claim 4, Jelinek teaches a gel-like solid selected from a group that includes agarose. See claim 6 of Jelinek. Furthermore, Jelinek teaches a polymer from which the matrix is made selected from a group that includes polyacrylamides. See claim 4 of Jelinek. Lu teaches a hydrogel shell is comprised of polyacrylamide (i.e. a hydrogel polymer) and alginate. See claim 88 of Lu. Regarding claim 5, Jelinek teaches that suitable nutrients include broth needed for the growth of said microorganisms are included in liquid precursor. See [0036]. In example 18, Jelinek teaches preparing E. coli in 20 ml of LB medium (i.e. liquid LB). See [0092]. Although Jelinek does not explicitly teach LB broth, it would have been obvious to a person of ordinary skill in the art prior to the effective filing date of the instantly claimed invention that the Jelinek’s LB medium is necessarily a broth, because Jelinek teaches a liquid volume of the LB medium. Regarding claim 7, Jelinek teaches a calorimetric and/or fluorescent detector for detecting the presence of bacteria. See claim 27 of Jelinek. Claim 10 is rejected under 35 U.S.C. 103 as being unpatentable over Jelinek (US 2006/0172371) and Lu (US 2019/0240356), as applied to claims 1, 4-5 and 7 above, and further in view of Super (US 2015/0064703). Regarding claim 10, Jelinek teaches a calorimetric and/or fluorescence detector that further comprises one or more antibiotic. See claim 8 of Jelinek. Jelinek teaches using a calorimetric and/or fluorescent detector for determining the antibiotic resistance of a bacterial strain. See claim 28 of Jelinek. Jelinek and Lu do not teach a kit. Super teaches kits for rapid determination of antibiotic susceptibility of a microbe. See [0003]. Super teaches a kit for determining antibiotic susceptibility of a microbe in a sample comprising an antibiotic. See claim 88 of Super. The kit can comprise a gel matrix for forming a detection substrate. See [0315]. It would have been obvious to a person of ordinary skill in the art prior to the effective filing date of the instantly claimed invention to organize Jelinek and Lu’s colorimetric biosensor with Jelinek’s antibiotic in a kit based Super’s suggestion. One of ordinary skill in the art would have been motivated to do so because Super suggests using kits for rapid determinations of antibiotic susceptibility. There would have been a reasonable expectation of success because Jelinek teaches a gel-like calorimetric and/or fluorescent detector (see claim 2 of Jelinek) comprising an antibiotic (see claim 8 of Jelinek), and Super teaches kits comprising a gel matrix (see [0135]) and an antibiotic (see claim 88 of Super). Response to Arguments Applicant's arguments filed 07/14/2026 have been fully considered to the extent that they might apply to the new grounds of rejection set forth above, but they do not apply to the new grounds of rejection set forth above. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to KIMBERLY C BREEN whose telephone number is (571)272-0980. The examiner can normally be reached M-Th 7:30-4:30, F 8:30-1:30 (EDT/EST). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, LOUISE HUMPHREY can be reached at (571)272-5543. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /LOUISE W HUMPHREY/Supervisory Patent Examiner, Art Unit 1657 /K.C.B./Examiner, Art Unit 1657
Read full office action

Prosecution Timeline

Sep 26, 2023
Application Filed
Apr 14, 2026
Non-Final Rejection mailed — §103
Jul 14, 2026
Response Filed
Aug 27, 2026
Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12742190
PRODUCTION OF FRUCTOSE FROM OLIGO-/ AND/OR POLYSACCHARIDES
4y 3m to grant Granted Sep 22, 2026
Patent 12698484
AN OMEGA-TRANSAMINASE MUTANT BASED ON ANCESTRAL SEQUENCE RECONSTRUCTION
2y 9m to grant Granted Aug 04, 2026
Patent 12644096
A METHOD FOR INCREASING ROMIDEPSIN PRODUCTION FROM FERMENTATION BROTH
4y 11m to grant Granted Jun 02, 2026
Patent 12577292
FERRITIN NANOCAGE FOR MULTI-DISPLAYING TRAIL TRIMER AND CANCER-TARGETING PEPTIDE AND USE THEREOF AS ANTICANCER AGENT
4y 6m to grant Granted Mar 17, 2026
Patent 12578329
REAGENT KIT CONTAINING POLYPEPTIDE FOR USE IN DETECTION OF INTERMOLECULAR INTERACTIONS
3y 10m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
24%
Grant Probability
81%
With Interview (+56.9%)
3y 5m (~5m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 80 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month